Second and third line chemotherapy in advanced breast cancer.
Alexopoulos
A
A
1st Dept. of Medical Oncology, St. Savas Hosp., Athens, Greece.
Rigatos
G
G
Stavrinidis
E
E
Stavrakakis
J
J
Scartsilas
C
C
Papacharalambous
A
A
D000505:Alopecia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D015251:Epirubicin; D016685:Mitomycin; D014750:Vincristine; D014747:Vinblastine